Market evolution: Amides (CN 2924) — 2015–2025

Introduction

This report examines the evolution of EU trade in Carboxyamide-function compounds; amide-function compounds of carbonic acid (CN 2924) over the 2015–2025 period. This product category covers a broad family of organic chemicals—including acyclic and cyclic amides, carbamates, and ureines—used across pharmaceutical, agrochemical, and specialty chemical industries.

The EU remains a net importer of CN 2924 products, with a structural trade deficit that widened from €1.17 billion in 2015 to €1.51 billion in 2025. Over this decade, however, the composition of that trade shifted dramatically: imports pivoted toward high-volume, lower-unit-price flows from Asia (especially China and India), while the EU's own exports moved up the value chain toward higher-priced products. Three major dynamics stand out—a decisive reorientation of import partners away from traditional European suppliers toward Asian producers; a divergence between quantity and value trajectories driven by product-mix and pricing effects; and a gradual improvement in the EU's strategic autonomy indicators despite continued dependence on external supply.

1. The Asian Pivot: A Fundamental Reorientation of Import Origins

China and India have displaced Switzerland and the UK as the EU's primary external suppliers

The most striking structural shift in the EU amide market over the past decade is the collapse of Switzerland's share and the surge of China and India. In 2015, Switzerland was the EU's dominant import partner for CN 2924, supplying goods worth €1.07 billion—more than half of total EU imports. By 2025, Swiss exports to the EU had fallen to €338 million, a decline of 68.3%. Meanwhile, China's share exploded from €234 million to €972 million (+315.5%), and India's grew from €126 million to €414 million (+227.9%).

Source: Top partners by value (imports)

The decline of Swiss dominance reflects both trade diversion and possible relocation of production

Switzerland's sharp decline in EU supply may partly be an accounting effect: as global chemical companies (several headquartered in Switzerland) shift production to lower-cost locations in Asia, shipments that previously entered the EU via Swiss intermediaries now originate directly from Chinese or Indian factories. The simultaneous rise of China and India, combined with the fall of Switzerland, is consistent with a broader trend of active pharmaceutical ingredient (API) and fine chemical manufacturing migrating eastward.

EU import concentration has decreased, indicating a more diversified supplier base

The Herfindahl-Hirschman Index (HHI) for EU import value fell from 3,326 in 2015 to 2,332 in 2025 (−29.9%). While an HHI of 2,332 still indicates a moderately concentrated import market, the trend toward diversification is positive from a supply-security perspective. The previous extreme concentration on Switzerland has given way to a more balanced portfolio, with China, India, the United States, and Switzerland each holding significant but non-dominant shares.

2. Volume–Value Divergence: The EU Exports Higher-Value Products While Importing Commodity-Grade Amides

EU export volumes have collapsed while export values have grown, signaling a major shift toward premium products

Between 2015 and 2025, EU export quantities fell from 161,909 tonnes to 99,448 tonnes (−38.6%), yet export values rose from €809 million to €918 million (+13.5%). This implies a dramatic increase in the average unit export price, from €4,993 per tonne to €9,224 per tonne (+84.7%).

Source: General Overview — Trade

The product-mix split between acyclic and cyclic amides explains much of this price divergence

Looking at the segment breakdown, two sub-categories dominate trade: acyclic amides (CN 292419) and cyclic amides (CN 292429).

• Acyclic amides (292419): By 2025, this category accounted for 105,097 tonnes of imports (71.5% of total import volume) but only €374 million in value (15.4% of total import value), at a unit price of approximately €3,551/t. This is a high-volume, commodity-grade segment.

• Cyclic amides (292429): By 2025, this category represented only 39,566 tonnes of imports (26.9% of volume) but a massive €2,031 million in value (83.8% of import value), at a unit price of approximately €51,312/t—more than 14 times the price of acyclic amides. This is the high-value, specialty segment that includes many pharmaceutical intermediates.

On the export side, the EU shipped 90,195 tonnes of acyclic amides (292419) worth €366 million (€4,051/t) and 6,702 tonnes of cyclic amides (292429) worth €504 million (€75,108/t). The EU thus demonstrates a strong competitive edge in high-value cyclic amides: these represent only 6.7% of export volume but 54.9% of export value.

EU production tells a story of massive value appreciation despite falling physical volumes

EU production volumes declined from 798 million kg to 630 million kg (−21.0%), yet production values surged from €957 million to €2,531 million (+164.4%). This confirms that the EU's amide industry has undergone a strategic move toward higher-margin specialty products, consistent with the broader trend of European chemical companies exiting commodity segments in favour of complex, high-value-added chemistry.

3. Strategic Autonomy and Market Resilience: Improving Indicators Amid Persistent Structural Dependencies

The EU's net import reliance has fallen meaningfully over the decade

The net import reliance for CN 2924 dropped from 56.8% in 2015 to 36.2% in 2025 (−36.4%). This significant improvement means the EU is covering a larger share of its domestic consumption from internal production. The lowest point was reached at 34.6%, suggesting the EU came close to achieving two-thirds self-sufficiency in amide-function compounds.

Source: Autonomy & Vulnerability

Export propensity has declined sharply, reflecting a reorientation toward the domestic market

The EU's export propensity fell from 64.7% to 33.8% (−30.9 percentage points). In 2015, the EU exported nearly two-thirds of its amide production; by 2025, that figure had halved. This suggests that a growing share of EU-produced amides is now consumed domestically—likely driven by strong demand from the European pharmaceutical sector for intermediates and APIs. The trade intensity indicator similarly declined from 88.1% to 65.3%, confirming that the EU amide market is becoming somewhat less exposed to international trade flows.

Persistent dependencies remain, concentrated in the high-value cyclic amide segment

Despite improvements in aggregate self-sufficiency, the EU continues to import cyclic amides (292429) worth over €2 billion annually—more than €51,000 per tonne. This segment, which includes many pharmaceutical intermediates and specialty chemicals, represents the core vulnerability. The concentration of supply from China (€972 million) and India (€414 million) in the broader CN 2924 category raises questions about geopolitical risk, especially given the strategic importance of pharmaceutical supply chains.

Volatility in bilateral flows underscores the fragility of specific trade relationships

The coefficient of variation analysis reveals elevated volatility across several key relationships:

• EU imports from the United Kingdom show a coefficient of variation of 1.11, indicating extreme instability—consistent with the disruption caused by Brexit.
• EU exports to Russia saw the most pronounced shock event in the dataset: a price shift of +261.9% centered on 2023, with an abnormality score of 36.1—likely reflecting the impact of EU sanctions on Russia following the invasion of Ukraine.
• A price shock of +50.6% in EU exports to the United States centered on 2022 (abnormality 14.5), affecting a flow that represents 41.3% of export value, may reflect post-COVID supply chain repricing or specific product shortages.

Conclusion

The EU amide market (CN 2924) has undergone a profound transformation over the 2015–2025 decade. The most visible change is geographic: Asian producers, led by China and India, have largely replaced Switzerland and the United Kingdom as the EU's principal external suppliers. This pivot has brought higher import volumes at generally lower unit prices for commodity-grade acyclic amides, while the EU has simultaneously upgraded its own export profile toward high-value cyclic amides priced at over €75,000 per tonne.

Strategic autonomy indicators have improved—net import reliance fell from 57% to 36%—but significant dependencies persist, particularly in the specialty cyclic amide segment that underpins the European pharmaceutical industry. The EU's productive base has shifted toward fewer tonnes but far greater value, a pattern consistent with the broader restructuring of the European chemical industry toward high-margin, knowledge-intensive products.

Key risks going forward include concentration of Asian import supply, volatility in bilateral relationships (exemplified by the Russia sanctions shock and Brexit-related UK disruptions), and the continued structural dependence on imported high-value intermediates. Policymakers should monitor whether the recent improvements in self-sufficiently are sustained, particularly as global supply chains continue to evolve in response to geopolitical tensions and industrial policy initiatives in both Europe and Asia.